| Literature DB >> 25530976 |
Jinghui Zhou1, Yuhuan Meng1, Shuai Tian1, Junhui Chen1, Mingyu Liu1, Min Zhuo1, Yu Zhang2, Hongli Du1, Xiaoning Wang3.
Abstract
Type 2 diabetes (T2D) is a prevalent disease that happens around the world and usually happens with insulin resistance. MicroRNAs (miRNAs) represented important roles in the suppression of gene expression and were proven to be related to human diseases. In this study, we used cynomolgus monkey fed with normal and high fatty diet (HFD), respectively, to analyze the miRNA expression profile in whole blood by deep sequencing. Finally in total 24 miRNAs with differential expression were filtered. Among them, miR-182 related to the insulin resistance by modulating FOXO1 and PI3K/AKT cascade and had the greatest copy number in the whole blood. Decrease of miR-182 in T2D cynomolgus individuals is completely consistent with the previous studies in human and rat. Integrating miR-182 tissue expression profile, target genes, and copy number in blood reveals that miR-182 plays a key role in crucial genes modulation, such as FOXO1 and BHLHE22, which leads to potential hyperglycemia and modulates the insulin secretion. In addition, miR-182 might regulate the processes of both cell proliferation and apoptosis that play crucial role in determining the cells' fate. Therefore, miR-182 can be a biomarker in diagnosis of the potential T2D that has benefits for medical purpose.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25530976 PMCID: PMC4235598 DOI: 10.1155/2014/760397
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
The physical indexes of the cynomolgus macaques.
| No. | Sex | Age (year) | Weight (kg) | GLUa (mmol/L) | HBA1C (%) | Fasting insulin (uU/mL) | HDL-CH (mmol/L) | TG (mmol/L) | LDL-CH (mmol/L) | CHOL (mmol/L) | Comment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 47 | M | 19 | 8.2 | 22.6 ± 2.9 | 10.0 ± 0.6 | 26.0 ± 3.0 | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.7 ± 0.1 | 2.8 ± 0.2 | Intact T2D |
| 64 | M | 18 | 6.9 | 17.0 ± 1.4 | 12.4 ± 1.5 | 7.7 ± 1.9 | 0.9 ± 0.1 | 2.1 ± 0.2 | 1.4 ± 0.7 | 2.9 ± 0.7 | Intact T2D |
| 8 | F | 22 | 5.3 | 7.9 ± 1.8 | 6.1 ± 0.2 | 44.1 ± 11.0 | 1.3 ± 0.1 | 1.1 ± 0.0 | 1.1 ± 0.1 | 2.3 ± 0.4 | Intact T2D |
| 52 | M | 18 | 9.2 | 2.8 ± 0.6 | 4.0 ± 0.0 | 26.9 ± 2.1 | 1.6 ± 0.0 | 0.3 ± 0.0 | 1.0 ± 0.1 | 2.5 ± 0.0 | Intact |
| 61 | M | 17 | 7.7 | 2.8 ± 0.6 | 4.1 ± 0.0 | 15.9 ± 12.7 | 1.4 ± 0.1 | 0.4 ± 0.3 | 1.1 ± 0.0 | 2.4 ± 0.1 | Intact |
| 1 | F | 18 | 6.1 | 3.5 ± 0.31 | 4.6 ± 0.2 | 30.7 ± 11.2 | 1.4 ± 0.0 | 1.3 ± 0.2 | 1.0 ± 0.3 | 2.5 ± 0.2 | Intact |
| 11 | M | 12 | 11.1 | 8.6 ± 4.3 | 8.5 ± 0.1 | 356.1 ± 62.9 | 0.7 ± 0.2 | 4.4 ± 0.3 | 1.6 ± 0. 3 | 4.0 ± 0.5 | HFD T2D |
| 25 | M | 9 | 11 | 12.7 ± 0.8 | 10.8 ± 1.6 | 229.2 ± 73.6 | 1.7 ± 0.1 | 1.1 ± 0.3 | 3.4 ± 1.8 | 5.0 ± 1.8 | HFD T2D |
| 9 | M | 18 | 11.8 | 7.6 ± 1.5 | 6.7 ± 0.7 | 125.2 ± 78.4 | 1.8 ± 0.3 | 2.3 ± 0.2 | 2.6 ± 0.2 | 4.3 ± 0.6 | HFD T2D |
| 31 | M | 12 | 11.5 | 3.2 ± 0.0 | 4.65 ± 0.2 | 361.9 ± 153.4 | 1.6 ± 0.1 | 2.1 ± 0.2 | 1.5 ± 0.2 | 3.6 ± 0.3 | HFD |
| 34 | M | 13 | 9 | 3.1 ± 0.2 | 3.9 ± 0.1 | 107.8 ± 8.1 | 1.9 ± 0.0 | 0.4 ± 0.1 | 1.3 ± 0.0 | 3.0 ± 0.0 | HFD |
| 6 | F | 21 | 6.5 | 4.6 ± 0.4 | 4.6 ± 0.3 | 115.6 ± 56.4 | 1.8 ± 0.1 | 0.7 ± 0.0 | 1.8 ± 0.2 | 3.7 ± 0.5 | HFD |
aGLU: glucose; HBA1C: glycosylated hemoglobin A1c; HDL-CH: high density lipoprotein cholesterol; TG: triglyceride; LDL-CH: low density lipoprotein cholesterin; CHOL: cholesterol.
Figure 1The general expression tendencies of the 24 specific miRNAs in All comparison, intact comparison, and HFD comparisongroups. The comparisons were carried out following the criteria where T2D individuals were compared with no-T2D individuals. All comparisons were carried out in all the monkeys without considering the diet conditions, while intact comparison was only in intact monkeys and HFD comparison was in HFD monkeys. (a) The Venn diagram represents the numbers of differential expressed miRNAs in All comparison (blue), intact comparison (green), and HFD comparison (red) groups. (b) The 7 specific miRNAs in the All comparison groups. All the miRNAs are in the same expression tendencies except miR-9. The positive values of the fold change mean that the miRNAs are upregulated in the T2D samples, whereas the negative values mean the downregulated expression. (c) The specific 7 miRNAs uniquely existed in the intact comparison group. Without miR-486-3p, miR-499a, and miR-99a in inconsistent expression between intact and HFD groups, others are in the same expression tendencies. (d) The 10 specific miRNAs uniquely existed in the HFD group. All of the miRNAs, except miR-196a and miR-96, are in inconsistent expression tendencies between the intact and HFD induced groups. Statistically significant differences are tested at P < 0.05 significance. The significance in t-test was labeled in black color, whilst that in ANOVA test was in red color (P * < 0.05, P ** < 0.01).
Figure 2The comparison between the no-T2D individuals in normal diet and HFD. The fold-change of each miRNA in no-T2D comparison was represented.
The details of the differential expressed miR-182 in the T2D individuals.
| Species and tissue | Fold change (T2D/normal) |
| Reference or accession ID |
|---|---|---|---|
| Human blood (lean) | −1.3956 | 0.2651 | GSE27645 |
| Human blood (obese) | −1.1258 | 0.7116 | GSE27645 |
| Human blood | −2.5800 | 0.0400 | [ |
| Rat blood | −1.8560 | 0.0050 | [ |
| Rat adipose | −3.5220 | 0.0010 | [ |
| Rat pancreas | −1.2590 | 0.0020 | [ |
| Rat skeletal muscle | −4.2260 | 0.0230 | [ |
| Rat liver | −2.6130 | 0.0110 | [ |
| Cynomolgus blood (All comparison) | −2.5629 | 0.0224 | — |
| Cynomolgus blood (intact comparison) | −1.7684 | 0.0047 | — |
| Cynomolgus blood (HFD comparison) | −3.8130 | 0.1645 | — |
|
| |||
|
|
| ||
Figure 3Putative regulation network of miR-182 related to the syndrome in T2D. The miR-182 can be linked to the syndrome of T2D according to the valid target genes analysis. The crucial genes and pathways that related to insulin resistance, insufficient insulin secretion, and the impairment of the tissues were represented in the figure.